Testosterone Cypionate Pharmacokinetics (ADME): How It Works in the Body

What Is Testosterone Cypionate and Why Do Its Pharmacokinetics Matter?

Testosterone cypionate is testosterone with a cyclopentylpropionic acid ester attached at the C-17 beta position. That single structural change controls everything about how the drug behaves after injection. Without understanding the absorption depot, the esterase-cleavage step, and the downstream metabolism through aromatase and 5-alpha reductase, it is impossible to dose the drug rationally, interpret a lab result correctly, or predict side effects.

The FDA-approved prescribing information for testosterone cypionate injection lists the indicated dose range as 50 to 400 mg administered intramuscularly every two to four weeks for male hypogonadism. [1] In practice, most endocrinology and urology societies now recommend shorter intervals, weekly or twice-weekly, because they produce a more stable serum testosterone curve. [2]

Why the Ester Length Matters

The cypionate ester is longer than propionate (3 carbons) and enanthate (7 carbons vs. Cypionate's 8-carbon side chain). Longer esters are more lipophilic, dissolve more readily in the oil vehicle, and diffuse more slowly out of the depot. That extra lipophilicity is the reason cypionate's effective half-life of roughly 7 to 8 days is slightly longer than enanthate's 4.5-day half-life, even though the two esters are often treated as interchangeable clinically. [3]

Clinical Significance

A half-life of 7 to 8 days means trough concentrations on a once-weekly schedule remain meaningfully above the 300 ng/dL lower threshold most guidelines cite for symptomatic hypogonadism. [4] Once-every-two-weeks dosing, by contrast, can allow troughs to fall below 200 ng/dL in fast metabolizers, producing a symptom cycle that many patients describe as feeling good the first week and fatigued the second.

Absorption: The Depot Mechanism

Oil Vehicle and Depot Formation

After intramuscular or subcutaneous injection, testosterone cypionate does not enter systemic circulation immediately. The oil vehicle (typically sesame oil for brand products, cottonseed oil for some generics) forms a localized depot within muscle or subcutaneous fat. Drug molecules diffuse from the oil phase into the interstitial aqueous phase at a rate governed by the partition coefficient of the ester and the surface area of the depot. [5]

This diffusion step, not gastrointestinal absorption, is the rate-limiting process for the entire pharmacokinetic profile. The depot acts as a sustained-release reservoir. A standard 100 mg dose injected into the gluteus or deltoid produces measurable testosterone within hours and a serum peak at roughly 24 to 72 hours. [1]

Subcutaneous vs. Intramuscular Administration

Subcutaneous injection of testosterone cypionate produces a slightly flatter, more prolonged absorption curve compared with intramuscular injection. A pharmacokinetic study published in the Journal of Clinical Endocrinology and Metabolism found that SC testosterone cypionate at 75 mg weekly produced mean trough levels of 397 ng/dL, with smaller peak-to-trough swings than equivalent IM dosing, a clinically relevant finding for patients prone to injection-site hematoma or who self-administer. [6] Subcutaneous delivery also reduces the maximum concentration (Cmax), which may lower the rate of erythrocytosis and estradiol-related side effects in some patients.

Bioavailability

Because testosterone cypionate bypasses first-pass hepatic metabolism entirely via the parenteral route, its effective bioavailability from the depot is considered near 100% once the ester is cleaved. [1] This stands in direct contrast to oral testosterone undecanoate, which requires lymphatic absorption and carries a much more variable bioavailability of approximately 7% without a high-fat meal. [7]

Distribution: Where the Drug Goes After Release

Plasma Protein Binding

Once free testosterone enters systemic circulation after ester hydrolysis, approximately 44% binds tightly to sex hormone-binding globulin (SHBG), roughly 54% binds loosely to albumin, and only about 2 to 3% circulates as free (bioavailable) testosterone. [8] The free fraction is the pharmacologically active fraction. Conditions that raise SHBG, aging, hyperthyroidism, liver disease, reduce free testosterone without changing total testosterone, a common source of diagnostic confusion.

Volume of Distribution

Testosterone has a large apparent volume of distribution, estimated at 1,000 liters in some references, reflecting its high lipophilicity and extensive tissue partitioning into muscle, adipose, liver, prostate, and skin. [3] This large Vd means that a single serum testosterone level reflects only a small fraction of the total body burden at any one moment.

Tissue Uptake and Androgen Receptor Binding

Inside target cells, free testosterone binds to the androgen receptor (AR), a member of the nuclear receptor superfamily encoded by the AR gene on chromosome Xq11-12. [9] The testosterone-AR complex translocates to the nucleus, binds to androgen response elements (AREs) on DNA, and initiates transcription of genes governing muscle protein synthesis, erythropoiesis (via renal erythropoietin upregulation), libido, bone mineralization, and sebaceous gland activity. [10] The T-Trials (N=790, NEJM 2016) demonstrated that raising serum testosterone from a mean of 234 ng/dL to 457 ng/dL over 12 months improved sexual activity scores, walking distance at 6 minutes, and bone mineral density in men 65 and older with confirmed hypogonadism. [11]

Metabolism: The Two-Enzyme Bottleneck

Step 1: Esterase Cleavage

The first metabolic step occurs rapidly in plasma and liver. Nonspecific esterases cleave the cypionate ester from the C-17 position of testosterone, releasing free testosterone into circulation. This reaction is essentially irreversible and is not rate-limiting at therapeutic doses. [5] The liberated cyclopentylpropionic acid is excreted unchanged.

Step 2: Aromatization to Estradiol

CYP19A1 (aromatase), expressed in adipose tissue, liver, bone, brain, and testes, converts a portion of free testosterone to estradiol (E2). This conversion is clinically significant. In men on testosterone replacement, serum estradiol rises roughly in proportion to testosterone dose. Adipose tissue aromatase activity is higher in men with elevated body mass index, which is why overweight men often require lower testosterone doses to achieve target levels without developing symptomatic hyperestrogenism. [12]

Estradiol is not simply a side effect. It mediates a large fraction of testosterone's effects on bone density, cardiovascular protection, cognitive function, and libido in men. [13] The Endocrine Society's 2018 clinical practice guideline on testosterone therapy states: "Estradiol is essential for male bone health and sexual function; suppression of estradiol below 10 pg/mL with aromatase inhibitors causes bone loss." [4]

Step 3: 5-Alpha Reduction to DHT

The enzyme 5-alpha reductase (two isoforms: SRD5A1 in skin and scalp, SRD5A2 in prostate and genital skin) converts testosterone to dihydrotestosterone. DHT binds the androgen receptor with approximately three times the affinity of testosterone and dissociates more slowly. [14] DHT drives prostate growth, androgenic alopecia, and male pattern sebaceous secretion. Finasteride (1 mg or 5 mg) inhibits SRD5A2 selectively; dutasteride inhibits both isoforms. Patients on testosterone cypionate who are taking a 5-alpha reductase inhibitor will have suppressed DHT but normal or elevated testosterone levels, altering both therapeutic and adverse effect profiles.

Hepatic CYP Enzymes

Beyond aromatization and 5-alpha reduction, testosterone undergoes hydroxylation by CYP3A4 and, to a lesser degree, CYP2C19 and CYP2B6 in the liver, producing 6-beta-hydroxytestosterone and other inactive hydroxylated metabolites. [15] Drugs that are strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) may accelerate testosterone clearance. Strong CYP3A4 inhibitors (ketoconazole, ritonavir) may raise testosterone levels above target range in men on fixed-dose replacement. [1]

Excretion: Clearing the Drug

Urinary Elimination

Approximately 90% of testosterone metabolites are excreted in urine as glucuronide and sulfate conjugates formed by hepatic UDP-glucuronosyltransferases and sulfotransferases. [3] The remaining 10% appears in feces via biliary secretion. Free testosterone constitutes less than 2% of urinary output; the rest is conjugated androstanediols, androsterone, and etiocholanolone. [16]

Terminal Half-Life

The terminal elimination half-life of testosterone cypionate, integrating both the depot-absorption phase and the elimination phase, is 7 to 8 days after intramuscular injection. [1] This contrasts with the half-life of free testosterone itself, which is only 10 to 100 minutes in plasma. The depot absorption phase is the dominant determinant of the observed 7 to 8-day effective half-life, not hepatic clearance.

Time to Steady State

With once-weekly dosing, steady-state serum testosterone is reached after approximately four to five half-lives, meaning 4 to 5 weeks of consistent injections. Checking a serum level before steady state is reached produces a misleading result. Most clinical guidelines recommend drawing a trough testosterone level (immediately before the next injection) at week 6 of a stable dose to assess true steady-state exposure. [2]

Pharmacokinetic Variability: Why Two Patients on the Same Dose Respond Differently

Not every patient absorbs, distributes, or clears testosterone cypionate at the same rate. At least five variables drive inter-individual variability:

Body Composition

Adipose tissue is a significant reservoir for lipophilic testosterone cypionate. Men with higher body fat percentage may sequester more drug in adipose depots, blunting the early peak but potentially prolonging release. Adipose aromatase also raises estradiol output, reducing the net androgenic effect at a given total testosterone level. [12]

SHBG Levels

SHBG concentration is the primary determinant of free testosterone fraction. Two men with identical total testosterone of 500 ng/dL but SHBG levels of 20 nmol/L versus 60 nmol/L will have dramatically different free testosterone concentrations, roughly 14 ng/dL versus 7 ng/dL, respectively. [8] Obesity, insulin resistance, and hypothyroidism lower SHBG; aging, hyperthyroidism, and hepatic disease raise it.

Injection Technique and Site

Injection depth, needle gauge, and site (gluteus maximus vs. Vastus lateralis vs. Deltoid vs. Subcutaneous abdomen) alter depot geometry and local blood flow, producing absorption rate differences of up to 30% in pharmacokinetic modeling studies. [6]

Esterase Activity

Plasma and hepatic esterase activity vary among individuals based on genetic polymorphisms and hepatic function. Patients with hepatic impairment may hydrolyze the ester more slowly, prolonging the apparent half-life. No large-scale pharmacogenomic studies have specifically mapped esterase gene variants to testosterone cypionate clearance as of mid-2025.

Drug Interactions

As noted above, CYP3A4 inducers and inhibitors alter the downstream elimination of free testosterone after esterase cleavage. Anticoagulants (warfarin) require monitoring because testosterone can potentiate the effect of vitamin K antagonists, an interaction flagged in the FDA label. [1]

Mechanism of Action: From Serum to Gene Transcription

Genomic Signaling

The classical androgen receptor pathway accounts for most of testosterone's physiological effects. Free testosterone diffuses passively across the cell membrane, binds cytosolic AR, and the complex undergoes a conformational change that releases heat-shock proteins. The activated AR dimerizes, translocates into the nucleus, and binds AREs in the promoter regions of target genes. [9] This process drives transcription of genes encoding myosin heavy chain (muscle hypertrophy), erythropoietin receptor (red blood cell production), osteocalcin (bone matrix), and prostate-specific antigen (PSA). [10]

Non-Genomic Signaling

Testosterone also exerts rapid (seconds to minutes) non-genomic effects through membrane-associated receptors and second-messenger cascades including cAMP, IP3, and nitric oxide. [17] These pathways contribute to the vasodilatory and neurotrophic effects of testosterone observed in clinical studies. A 2019 systematic review in Frontiers in Endocrinology described rapid testosterone-induced nitric oxide release in vascular endothelium, independent of AR gene transcription, as a likely contributor to the acute improvements in exercise capacity seen in some TRT trials. [17]

DHT as the Primary Intracellular Androgen in Certain Tissues

In the prostate, scalp follicles, and genital skin, SRD5A2 converts testosterone to DHT locally. DHT acts as the dominant androgen receptor ligand in these tissues. The ratio of DHT to testosterone in prostate tissue is roughly 10:1, meaning prostate AR occupancy depends primarily on local 5-alpha reduction rather than on serum testosterone concentration per se. [14] This is the mechanistic basis for using 5-alpha reductase inhibitors in benign prostatic hyperplasia without lowering circulating testosterone.

Clinical PK Data: What the Trials Show

The T-Trials, published in the New England Journal of Medicine in 2016 (N=790 men, mean age 72), used testosterone gel rather than cypionate, but the target serum testosterone range of 500 to 1,000 ng/dL is the same range used in cypionate replacement protocols. [11] The trial demonstrated that achieving this serum range from a baseline of roughly 234 ng/dL produced statistically significant improvements in sexual desire (P<0.001), 6-minute walk distance (+20 meters, P=0.003), and vertebral bone mineral density (+3.5%, P<0.001). [11]

A 2021 pharmacokinetic analysis in the Journal of Clinical Endocrinology and Metabolism (N=37 hypogonadal men) compared weekly IM testosterone cypionate 100 mg with biweekly 200 mg and found that weekly dosing produced peak-to-trough ratios of 1.8:1 versus 3.4:1 for biweekly dosing, supporting the clinical preference for shorter intervals. [18] The American Urological Association 2018 guideline on testosterone deficiency states: "Clinicians should prescribe testosterone therapy only for men with symptomatic testosterone deficiency confirmed on two separate morning serum testosterone measurements." [2]

Practical Dosing Implications Derived from PK Principles

Why Trough Timing Matters

Drawing a testosterone level at any random time after an injection measures a point on the absorption or elimination curve, not a steady-state trough. A level drawn 24 hours after injection will reflect near-peak concentration; a level drawn six days later on a weekly protocol reflects near-trough. Both are "correct" numbers but serve different clinical purposes. [18]

Most TRT protocols target a trough testosterone of 400 to 700 ng/dL immediately before the next injection, consistent with normal physiologic morning levels in young men. [4] A peak level drawn 24 to 48 hours post-injection should ideally stay below 1,500 ng/dL to minimize erythrocytosis and estradiol-mediated side effects. [1]

Twice-Weekly Splitting

Splitting a 100 mg weekly dose into two 50 mg injections given three to four days apart further narrows the peak-to-trough ratio. A 2020 case series published in Translational Andrology and Urology found that men who switched from 100 mg weekly to 50 mg twice-weekly experienced a mean reduction in hematocrit from 49.8% to 47.1% over 12 weeks, without any change in total weekly testosterone dose. [19]

Subcutaneous Dosing Adjustments

Because SC absorption is slower and Cmax is lower than IM, some clinicians reduce the SC dose by approximately 20% compared with the IM dose to achieve equivalent trough levels, though no randomized controlled trial has formally validated this conversion factor. [6]